Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 4, 2012, Pages 237-247

  He, Yan Ling ^a   Ito, Harunobu ^b   Yamaguchi, Masayuki ^b   Terao, Shinji ^b   Shimada, Sayaka ^b   Irie, Shin ^c   Sekiguchi, Kaneo ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA K K   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

Author keywords

Glucagon like peptide 1; Glucose; Meal timing; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PLACEBO; VILDAGLIPTIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; ECG ABNORMALITY; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; FOOD; FOOD DRUG INTERACTION; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHARMACOKINETICS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOOTH PAIN;

ADAMANTANE; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EATING; FEEDING BEHAVIOR; FEMALE; FOOD-DRUG INTERACTIONS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTESTINAL ABSORPTION; JAPAN; MALE; MIDDLE AGED; NITRILES; POSTPRANDIAL PERIOD; PYRROLIDINES; TREATMENT OUTCOME;

EID: 84859076159     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201631     Document Type: Article

References (38)

1. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 2078-2084. doi:10.1210/jc.2003-031907 PubMed (Pubitemid 38619835)
2. Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005; 28: 1936-1940. doi:10.2337/diacare.28.8.1936PubMed (Pubitemid 41060966)
3. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009; 11: 589-595. doi:10.1111/j.1463-1326.2008. 01023.x PubMed
4. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895. doi:10.2337/dc06-1732 PubMed
5. Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2008; 68: 2387-2409. doi:10.2165/0003495- 200868160-00009 PubMed
6. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007; 39: 218-223. doi:10.1055/s-2007-970422 PubMed (Pubitemid 46580622)
7. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3: 153-165. doi:10.1016/j.cmet.2006.01.004 PubMed
8. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res. 2009; 41: 905-909. doi:10.1055/s-0029-1234042 PubMed
9. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008; 10: 1047-1056. doi:10.1111/j.1463-1326.2008.00859.x PubMed
10. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007; 9: 166-174. doi:10.1111/j.1463-1326.2006.00684.x PubMed (Pubitemid 46206560)
11. Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011; 33: 1096-1103. doi:10.1016/j.clinthera.2011.07.005 PubMed
12. He YL, Barilla D, Ligueros-Saylan M, Rivere G-J, Campestrini J, Pratapa P. The pharmacokinetics and DPP-4 inhibition of LAF237 in healthy volunteers. J Clin Pharmacol. 2004; 44: 1212.
13. He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008; 48: 85-95. doi:10.1177/0091270007307880 PubMed (Pubitemid 350292271)
14. He YL, Sabo R, Campestrini J, Wang Y, Riviere GJ, Nielsen JC, Rosenberg M, Ligueros-Saylan M, Howard D, Dole WP. The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol. 2008; 65: 338-346. doi:10.1111/j.1365- 2125.2007.03031.x PubMed (Pubitemid 351316915)
15. He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007; 46: 577-588. doi:10.2165/00003088-200746070-00003 PubMed (Pubitemid 47025358)
16. He YL, Valencia J, Zhang Y, Schwartz SL, Ligueros-Saylan M, Foley J, Dole WP. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes. Br J Clin Pharmacol. 2010; 70: 34-42. doi:10.1111/j.1365-2125.2010.03652.x PubMed
17. He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007; 47: 633-641. doi:10.1177/0091270006299137 PubMed (Pubitemid 46632151)
18. He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int J Clin Pharmacol Ther. 2010; 48: 582-595. PubMed
19. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78: 675-688. doi:10.1016/j.clpt. 2005.09.002 PubMed (Pubitemid 41773643)
20. Kalbag JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care. 2001; 24: 73-77. doi:10.2337/diacare.24.1.73 PubMed
21. Karim A, Covington P, Christopher R, Davenport M, Fleck P, Li X, Wann E, Mekki Q. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010; 48: 46-58. PubMed
22. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999; 20: 876-913. doi:10.1210/er.20.6.876 PubMed (Pubitemid 30647076)
23. Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009; 83: 233-240. doi:10.1016/j.diabres.2008.10.006 PubMed
24. Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm. 2007; 64: 1265-1273. doi:10.2146/ajhp060564 PubMed (Pubitemid 47216194)
25. Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. Diabet Med. 2006; 23: 240-245. doi:10.1111/j.1464-5491.2006.01800.x PubMed
26. Luzio SD, Anderson DM, Owens DR. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects. J Clin Endocrinol Metab. 2001; 86: 4874-4880. doi:10.1210/jc.86.10.4874 PubMed (Pubitemid 33020535)
27. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, adipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 4888-4894. doi:10.1210/jc.2004-2460 PubMed (Pubitemid 41159387)
28. Patel CG, Zhang J, Li L, Gooding L, Croop R, Li T, Boulton DW. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol. 2010; 50: 1211-1216. doi:10.1177/0091270009360532 PubMed
29. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 76: 132-138. doi:10.1016/j.diabres.2006.12.009 PubMed (Pubitemid 46240373)
30. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006; 38: 423-428. doi:10.1055/s-2006-944546 PubMed (Pubitemid 44047965)
31. Rijkelijkhuizen JM, McQuarrie K, Girman CJ, Stein PP, Mari A, Holst JJ, Nijpels G, Dekker JM. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses. Metabolism. 2010; 59: 502-511. doi:10.1016/j.metabol.2009.07.039 PubMed
32. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005; 7: 692-698. doi:10.1111/j.1463-1326.2005.00539.x PubMed (Pubitemid 41601073)
33. Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009; 11: 571-578. doi:10.1111/j.1463-1326.2008.01021.x PubMed
34. Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007; 46: 93-108. doi:10.2165/00003088-200746020-00001 PubMed (Pubitemid 46193056)
35. Serra D, He YL, Bullock J, Riviere GJ, Balez S, Schwartz S, Wang Y, Ligueros-Saylan M, Jarugula V, Dole WP. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int J Clin Pharmacol Ther. 2008; 46: 349-364. PubMed (Pubitemid 352005928)
36. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999; 37: 213-255. doi:10.2165/00003088-199937030-00003 PubMed
37. Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, Howard D, Dole WP. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007; 47: 1152-1158. doi:10.1177/0091270007304313 PubMed
38. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003; 88: 2706-2713. doi:10.1210/jc.2002-021873 PubMed (Pubitemid 36724446)